Enzene Biosciences, Ltd., a global biotech company based in Pune, India, will invest $50 million to open a state-of-the-art biopharmaceutical manufacturing plant in New Jersey. Operations in the ...

Enzene Biosciences’ state-of-the-art manufacturing facility will bring hundreds of jobs and generate $50 million in economic investments in our state, further solidifying New Jersey’s position ...

At Enzene Biosciences, a subsidiary of Alkem Laboratories, developers have embraced the transition by adopting a fully connected continuous manufacturing ...

Enzene Biosciences, a unit of India’s Alkem Laboratories, has unveiled plans to open a $50 million manufacturing facility near Princeton, New Jersey. The CDMO expects to hire as many as 300 new ...

Enzene Biosciences, a Pune-based biopharmaceutical and contract development and manufacturing organization (CDMO), has launched its first manufacturing site in New Jersey, the United States.

Enzene Biosciences launches Cetuximab for cancer treatment. Cetuximab binds to specific cancer cell surface receptors (EGFR) and competitively inhibits the epidermal growth factor (EGF) binding.

Enzene has a patented connected continuous biologics manufacturing facility to monoclonal antibodies (mAb) in Pune. (IE) Biopharmaceutical company, Enzene Biosciences, a subsidiary of Alkem Labs ...

As reported by HealthCareRadius in India, on February 23, 2023, Enzene Biosciences, a subsidiary of Alkem Laboratories, announced commencement of commercial supplies of its biosimilar adalimumab ...

Pune-based Enzene Biosciences has launched the Ranibizumab the seventh biosimilar a recombinant Fab used as a treatment for neovascular age-related macular degeneration (AMD). The company further ...

PUNE: Enzene Biosciences Ltd., a leading biopharmaceutical company offering integrated Contract Development and Manufacturing (CDMO) services for Biologics, has announced the inauguration of its ...

Ultimately, Enzene Biosciences aims to gradually expand its operations across the five major markets for biologics and biosimilars, i.e. the EU, USA, Canada, Australia, and Japan, with the ulterior ...